Navigation Links
AstraZeneca to Support Drug-Induced Liver Injury Network at the National Institutes of Health
Date:5/27/2010

BETHESDA, Md., May 27 /PRNewswire/ -- A new public-private partnership between AstraZeneca and NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) will focus on supporting the work of the Drug-Induced Liver Injury Network (DILIN).  DILIN is a group working to bring together essential scientific and financial resources to better understand drug-induce liver injury as well as effective screening, diagnostic and treatment options.  

Drug-induced liver injury, whether caused by prescription or non-prescription medication, is the most common cause of acute liver failure in the United States. It is the major reason for non-approval, withdrawal and limiting the prescribing of medications by the Food and Drug Administration.

Under the terms of the partnership, AstraZeneca will join other companies to provide funding for the project.  AstraZeneca will also have a seat on a DILIN scientific board, a group convened by FNIH that includes representatives of all the partners in this endeavor, to provide expertise and input on scientific and technical matters.  No details of the financial support were disclosed.  

"AstraZeneca is keen to support this important project to help the industry and the medical community better understand and mitigate the risks of liver damage associated with the use of some medicines," said Joachim Forsgren, VP and Global Head of Patient Safety at AstraZeneca.  "The safety of patients who need drugs to treat many different kinds of conditions and illnesses is paramount in both developing new medicines and safely and effectively using products currently on the market. We want to play our part in furthering this critical work, which will provide valuable insight to all those engaged in the research and development of drugs."

"We welcome the support of AstraZeneca's underlying commitment to work with the Foundation for NIH, and NIH, as we pursue advances in research and potential treatment options for drug-induced liver injury. Bringing together a team of experts in a collaborative environment is essential to this project's overall success," said Foundation for NIH Chairman, Charles A. Sanders, M.D.  

NIDDK launched the Drug-Induced Liver Injury Network in 2004 to address this increasingly frequent health problem, The network gathers clinical information and biological specimens in cases of suspected liver injury due to drug and/or herbal remedy use and promotes research on the underlying causes, means of prevention, and approaches to management and therapy.

NOTES TO EDITORS:

Foundation for NIH.   For additional information about the Foundation for NIH, please visit www.fnih.org.

Established by the United States Congress to support the mission of the NIH—improving health through scientific discovery in the search for cures—the Foundation for NIH is a leader in identifying and addressing complex scientific and health issues. The foundation is a non-profit, 501(c)(3) corporation, which raises private-sector funds for a broad portfolio of unique programs that complement and enhance NIH priorities and activities.

NIDDK. For more information, please visit www.niddk.nih.gov.

DILIN. Additional details on DILIN are available at the project website, https://dilin.dcri.duke.edu/.

About AstraZeneca.  For more information, please visit: www.astrazeneca.com.


'/>"/>
SOURCE Foundation for the National Institutes of Health
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AstraZeneca Donates $1 Million for Christiana Care Health Systems Wilmington Hospital Project
2. Remarks as Prepared for Delivery By Attorney General Eric Holder at the AstraZeneca Settlement Announcement
3. Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing
4. Palatin Technologies, Inc. Receives $2.5 Million from AstraZeneca
5. AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma
6. AstraZeneca and Dako Sign Agreement to Develop Companion Diagnostics for Cancer Treatments
7. AstraZeneca Offers Online Enrollment and Additional Improvements to Patient Assistance Program
8. Novexel to be Acquired by AstraZeneca
9. AstraZeneca Medicare Part D Patient Assistance Program No Longer Requires Co-Pays
10. U.S. Court of Appeals Upholds AstraZeneca AWP Settlement
11. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global ... that its MyDario product is expected to appear on The Dr. Oz ... Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked ... The segment features ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
Breaking Medicine Technology:
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... Milford, NJ (PRWEB) , ... October 13, 2017 , ... ... weekend at scenic Alexandria Park in Milford, NJ. This free event, sponsored by ... and physical activity. The fun run is geared towards children of all ages; ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
Breaking Medicine News(10 mins):